CLINUVEL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.39 AUD | +2.87% |
|
+3.99% | -3.81% |
| 18/06 | Clinuvel Pharmaceuticals' Afamelanotide Found Effective in Fair-Skinned Parkinson’s Patients | MT |
| 18/06 | CLINUVEL Announces A Novel Clinical Program | CI |
Evolution of the average Target Price on Clinuvel Pharmaceuticals Limited
Price target over the last 5 years
History of analyst recommendation changes
5ea137a6fb7d045ff.cCr6AJ9qDDq-pSmy0OgTXDP7HTqhcoc1dTgtw52ErbQ.GR-9Yu0Lbl7M9BzRiLpiNFCYQnjCSsN9R1ofqPz31-Ebc7dh9zB9fYnfGQ~3711407c5dd41db3d14fcc450bb54c35
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.39
AUD
Average target price
25.6
AUD
Spread / Average Target
+66.35%
High Price Target
46.3
AUD
Spread / Highest target
+200.84%
Low Price Target
16
AUD
Spread / Lowest Target
+3.96%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Clinuvel Pharmaceuticals Limited
| Morgans Financial |
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
- Stock Market
- Equities
- CUV Stock
- Consensus Clinuvel Pharmaceuticals Limited
